新辅助化疗和间隔剖腹术在晚期卵巢癌中的作用。
The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.
作者信息
Huober J, Meyer A, Wagner U, Wallwiener D
机构信息
University of Tuebingen, Dept. of Gynecology and Obstetrics, Schleichstrasse 4, 72076 Tuebingen, Germany.
出版信息
J Cancer Res Clin Oncol. 2002 Mar;128(3):153-60. doi: 10.1007/s00432-001-0312-3. Epub 2002 Jan 29.
Abstract
Radical debulking surgery allows for optimal cytoreduction in less than 50% of patients with advanced ovarian cancer. In spite of highly efficient chemotherapeutic regimens, the prognosis of patients with residual tumor masses larger than 1 cm in diameter following staging laparotomy is very poor. This observation led to the initiation of numerous trials evaluating the feasibility and efficiency of the use of primary chemotherapy followed by interval laparotomy in women with advanced ovarian cancer. The available data is presented and discussed in this review.
摘要
根治性减瘤手术仅能使不到50%的晚期卵巢癌患者实现最佳细胞减灭。尽管化疗方案高效，但分期剖腹手术后残留肿瘤直径大于1 cm的患者预后很差。这一观察结果促使开展了许多试验，评估晚期卵巢癌女性患者先进行初始化疗然后行中间性剖腹手术的可行性和有效性。本综述展示并讨论了现有数据。
相似文献
1
The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.新辅助化疗和间隔剖腹术在晚期卵巢癌中的作用。
J Cancer Res Clin Oncol. 2002 Mar;128(3):153-60. doi: 10.1007/s00432-001-0312-3. Epub 2002 Jan 29.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
4
Surgical cytoreduction for recurrent epithelial ovarian cancer.复发性上皮性卵巢癌的手术细胞减灭术。
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. doi: 10.1002/14651858.CD008765.pub3.
5
A systematic overview of chemotherapy effects in ovarian cancer.卵巢癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):340-60. doi: 10.1080/02841860151116420.
6
Efficacy and safety of NeoAdjuvant chemotherapy with or without tIslelizumab followed by debulking surgery for oVarian cancEr (NAIVE study) in China: study protocol of an open-label, phase II, randomised controlled trial.中国新辅助化疗联合或不联合替雷利珠单抗随后进行减瘤手术治疗卵巢癌（NAIVE研究）的疗效和安全性：一项开放标签、II期、随机对照试验的研究方案
BMJ Open. 2025 Feb 5;15(2):e092545. doi: 10.1136/bmjopen-2024-092545.
7
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性（广泛）手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
8
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD005343. doi: 10.1002/14651858.CD005343.pub3.
9
Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.上皮性卵巢癌的治疗结果：开展策略性试验以解决手术最佳时机问题的时候了。
Int J Gynecol Cancer. 2015 Jul;25(6):993-9. doi: 10.1097/IGC.0000000000000461.
10
Interval debulking surgery for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的间隔减瘤手术
Cochrane Database Syst Rev. 2016 Jan 9;2016(1):CD006014. doi: 10.1002/14651858.CD006014.pub7.
引用本文的文献
1
Therapeutic effect of two transition metal coordination polymers on ovarian cancer by regulating the expression of estrogen receptor.两种过渡金属配位聚合物通过调节雌激素受体表达对卵巢癌的治疗作用
Des Monomers Polym. 2022 Feb 9;25(1):19-24. doi: 10.1080/15685551.2022.2033432. eCollection 2022.
2
Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.为新诊断的晚期卵巢癌患者选择最佳治疗策略。
World J Methodol. 2015 Dec 26;5(4):196-202. doi: 10.5662/wjm.v5.i4.196.
3
Comparison of Platinum-based Neoadjuvant Chemotherapy and Primary Debulking Surgery in Patients with Advanced Ovarian Cancer.铂类新辅助化疗与原发性肿瘤减灭术治疗晚期卵巢癌患者的比较
J Obstet Gynaecol India. 2013 Dec;63(6):405-9. doi: 10.1007/s13224-013-0425-z. Epub 2013 Aug 14.
4
Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery.晚期卵巢癌的胸腔转移：CT 与电视辅助胸腔镜手术的比较。
J Gynecol Oncol. 2011 Dec;22(4):260-8. doi: 10.3802/jgo.2011.22.4.260. Epub 2011 Dec 5.
5
Multidetector CT predictors of incomplete resection in primary cytoreduction of patients with advanced ovarian cancer.多排 CT 预测晚期卵巢癌患者初次细胞减灭术不完全切除的因素。
Eur Radiol. 2010 Jan;20(1):100-7. doi: 10.1007/s00330-009-1533-0. Epub 2009 Aug 6.
6
Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy.III/IV期卵巢癌的新辅助化疗或初次手术：诊断性腹腔镜检查的作用
BMC Cancer. 2009 Jun 6;9:171. doi: 10.1186/1471-2407-9-171.
7
Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI.卵巢癌的放射学分期：影像学表现及CT与MRI的作用
Eur Radiol. 2007 Dec;17(12):3223-35. doi: 10.1007/s00330-007-0736-5. Epub 2007 Aug 14.
8
Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients.晚期卵巢癌治疗中辅助化疗与新辅助化疗的比较：一项对574例患者的回顾性研究
BMC Cancer. 2006 Jun 8;6:153. doi: 10.1186/1471-2407-6-153.
9
The role of interval debulking surgery in ovarian cancer.间歇性肿瘤细胞减灭术在卵巢癌中的作用。
Curr Oncol Rep. 2003 Nov;5(6):473-81. doi: 10.1007/s11912-003-0008-8.
Zotero 插件